Latest Therapeutics News

Page 13 of 62
Actinogen Medical has locked in a $4.3 million tranche of non-dilutive funding to support its pivotal Alzheimer’s disease trial, reinforcing its financial position as it nears critical interim and final results.
Ada Torres
Ada Torres
27 Jan 2026
Cynata Therapeutics has successfully raised $1.2 million through an At-The-Market equity raise, issuing shares at a discount to support its ongoing clinical programs. This capital injection aims to bolster working capital as the company advances its proprietary stem cell therapies.
Ada Torres
Ada Torres
23 Jan 2026
Nyrada Inc. has secured ethics approval to launch a Phase IIa clinical trial for its heart attack drug Xolatryp®, with patient recruitment set for March 2026. The company maintains a solid cash position of AU$7.12 million as it expands its research into oncology.
Ada Torres
Ada Torres
23 Jan 2026
Arovella Therapeutics has filed an IND application for its lead CAR-iNKT therapy ALA-101, selected a CRO for its upcoming phase 1 trial, and secured $19.4 million in cash to fund clinical progress and pipeline expansion.
Ada Torres
Ada Torres
23 Jan 2026
PYC Therapeutics has reported significant progress across its four RNA therapeutic programs targeting rare genetic diseases, supported by a strong cash position of $121 million at the end of 2025. Key clinical milestones and regulatory plans set the stage for upcoming trial readouts and potential market entry.
Ada Torres
Ada Torres
23 Jan 2026
Invex Therapeutics reports promising new data from its collaboration with Tessara Therapeutics on Exenatide’s potential in Alzheimer’s disease, alongside significant board changes and a solid cash position at quarter’s end.
Ada Torres
Ada Torres
22 Jan 2026
LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.
Ada Torres
Ada Torres
22 Jan 2026
Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.
Ada Torres
Ada Torres
22 Jan 2026
Noxopharm has successfully completed the final multiple-dose cohort of its HERACLES trial for SOF-SKN™, reporting no significant safety concerns and paving the way for Phase II-enabling studies.
Ada Torres
Ada Torres
21 Jan 2026
Telix Pharmaceuticals has met its upgraded FY 2025 revenue guidance with US$804 million, driven by strong growth in its Precision Medicine segment and the successful US launch of Gozellix. The company also advanced multiple clinical trials and announced a strategic collaboration with Varian to combine radiopharmaceuticals with radiation therapy.
Ada Torres
Ada Torres
20 Jan 2026
Neurizon Therapeutics has secured trademark protection for its NEURIZON® brand across major pharmaceutical markets, reinforcing its intellectual property strategy as it advances its lead drug candidate NUZ-001.
Ada Torres
Ada Torres
20 Jan 2026
Atomo Diagnostics has locked in exclusive global rights to a novel liver function test that rapidly detects liver injury, expanding its footprint in point-of-care diagnostics. The test, delivered on Atomo’s Pascal platform, targets drug-induced liver injury and chronic liver conditions with significant commercial potential.
Ada Torres
Ada Torres
20 Jan 2026